Cluster Headache Market is Segmented By Drug Type (Calcium Channel Blockers, Corticosteroids, Local Anaesthetics, Lithium carbonate, Ergot Alkaloids, Others), By Type (Episodic, Chronic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Cluster Headache Market Overview
Cluster Headache Market is estimated to reach at a CAGR of 7.55% during the forecast period (2023-2030). Cluster headaches are one of the most painful headaches, as they occur in cyclical patterns of cluster periods. A cluster headache is characterised by severe pain in or around one eye on one side of the head that wakes one up in the middle of the night.
Cluster Headache Market Summary and Scope
|
Metrics |
Details |
|
Market CAGR |
7.55% |
|
Segments Covered |
By Drug Type, By Type, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click Here
Cluster Headache Market Dynamics and Trends
The factors influencing the global cluster headache market are the rising research and development activities and the increasing prevalence of cluster headaches.
The rising research and development activities are expected to drive the global cluster headache market in the forecast period
Cluster headache is one of the most common types of headaches. Patients experience attacks of severe unilateral pain that last 15 to 180 minutes and are in the orbital, retro-orbital, or temporal regions. Attacks can frequently happen anywhere from one to eight times per day. The disease gets its name because attacks occur in clusters that last weeks or months, with remission periods in between. These remission periods are not present in chronic cluster headaches. There are both acute and prophylactic treatment options currently available and recommended. Acute treatment with triptans can stop cluster headache attacks. There isn't much research into which triptan is the most effective. Sumatriptan or zolmitriptan, administered subcutaneously or intranasally, be effective abortive treatments. These triptans are ideal for stopping a cluster headache attack due to their quick onset of action. Intranasal administration of sumatriptan or lidocaine, oral zolmitriptan, sphenopalatine ganglion (SPG) stimulation, and subcutaneous administration of octreotide are all options for treating acute attacks. Triptans are not recommended if a patient has a history of cardiovascular disease. Years of clinical experience have shown that it should be a reason for caution rather than a complete ban. Oxygen (100 percent, 6–12 L/minute) is a tried-and-true alternative that has been shown to stop a significant number of cluster headache attacks. Moreover, on 4th June 2019, The FDA approved galcanezumab-gnlm (Emgality, Lilly) to treat cluster headaches, making it the first migraine drug.
The side effects associated with the cluster headache medication are expected to hamper the market growth
Verapamil (Calan SR, Verelan) is a calcium channel blocker frequently used to prevent cluster headaches. Other medications may interact with verapamil. In some cases, longer-term use is required to treat chronic cluster headaches. The possible side effects are constipation, nausea, fatigue, ankle swelling, and low blood pressure. Prednisone (Prednisone Intensol, Rayos) and other anti-inflammatory drugs known as corticosteroids, such as prednisone (Prednisone Intensol, Rayos), are fast-acting preventive medications that may help many people with cluster headaches. Although corticosteroids may be a good option for a few days, they are not recommended for long-term use due to serious side effects such as diabetes, hypertension, and cataracts. Hence, with the increasing side effects associated with cluster headache medication, the market is expected to be hampered.
COVID-19 Impact Analysis on Cluster Headache Market
COVID-19 causes headache, which is a symptom of systemic viral infections. According to recent research, 8% of COVID-19 infection patients complained of headaches. The presence of a headache does not help with COVID-19 infection diagnosis or prognosis. Infection with COVID-19 causes headache, which is likely to coexist with fever and may be dependent on it. Steroid use can cause immunosuppression and make people more susceptible to COVID-19 infection. It may be necessary to use steroids to stop a cluster attack in certain diseases (such as cluster headache). A doctor should carefully consider the use of steroids and will determine the doses and posology in each case based on treatment guidelines. To reduce the risk of infection, it is currently recommended that the number of days on steroid treatment be reduced. Hence, an increasing prevalence of headaches in patients infected with covid-19 is expected to drive market growth.
Cluster Headache Market Segmentation Analysis
The calcium channel blockers segment is expected to dominate the market growth in the forecast period
Calcium channel blockers may be the most effective CH (Cluster Headache) prevention agents. It's possible to combine them with ergotamine or lithium. Verapamil may be the most effective calcium channel blocker, though others such as nimodipine and diltiazem have also been effective. Because of the cyclical nature of CH, which is like that of bipolar disorders, lithium has been suggested as a treatment option. It effectively treats bipolar mood disorder, another cyclic illness, and prevents CH (especially in its more chronic forms). Although responses vary (with chronic CH patients being more responsive), lithium remains the first-line treatment for CH. After the dramatic relief seen in the first week, the effect tends to fade. According to a recent report, the current therapeutic actions of available Ca2+ channel blockers are primarily limited to cardiovascular disorders. However, there is one exception: cluster headaches. As a result, high-dose verapamil is becoming a more common preventive treatment for cluster headaches, and verapamil is now the mainstay in cluster headache prevention. The dose of verapamil required for the prevention of cluster headaches varies significantly. As a result, depending on the effect and adverse events, doses ranging from 240 mg to 960 mg are recommended. Even higher doses (1200 mg) are required in a few patients. This could be due to pharmacokinetic or pharmacodynamic variability, as has been suggested in the treatment of acute migraine.
Cluster Headache Market Geographical Share
North America region is expected to hold the largest market share in the global cluster headache market
The increasing prevalence of cluster headache and the increased healthcare infrastructure is expected to drive the market growth.
Cluster headache affects about one in every 1,000 adults in the United States. According to studies, the one-year prevalence can reach 53 per 100,000 adults. The average age of onset is between 20 and 40 years. The overall male-to-female ratio is 4.3, but chronic cluster headache has a much higher male-to-female ratio than episodic cluster headache (15 and 3.8, respectively). Cluster headaches that occur regularly are six times more common than those that occur regularly. Cluster headache has a significant socio-economic impact and associated morbidity; nearly 80% of patients say it limits their daily activities.
Moreover, on 4th June 2019, Emgality (galcanezumab-gnlm) solution for injection was approved by the US Food and Drug Administration to treat episodic cluster headache in adults. Emgality is the first FDA-approved drug to reduce the frequency of episodic cluster headache attacks, a painful and often debilitating condition.
Cluster Headache Companies and Competitive Landscape
The global cluster headache market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are Grünenthal, AbbVie Inc., Allergan, Merck & Co., Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Eli Lilly and Company
Eli Lilly and Company
Overview: Eli Lilly and Company is an American pharmaceutical company with offices in 18 countries and headquarters in Indianapolis, Indiana. Its goods are sold in more than 125 countries. In 1876, the company was established.
Product Portfolio: Emgality is the first FDA-approved drug to reduce the frequency of episodic cluster headache attacks, a painful and often debilitating condition.
Key Development: On 4th June 2019, Emgality (galcanezumab-gnlm) solution for injection was approved by the US Food and Drug Administration for the treatment of episodic cluster headache in adults.
